Sean B. Wharton

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: August 26, 2026

Rethinking obesity management targets: Findings from an international MoSCoW prioritization workshop.

Rethinking obesity management targets: Findings from an international MoSCoW prioritization workshop.

Journal: Obesity pillars

Published: July 07, 2026

Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.

Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.

Journal: PloS one

Published: June 22, 2026

Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.

Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.

Journal: Postgraduate medicine

Published: June 13, 2026

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Journal: The New England journal of medicine

Published: June 08, 2026

Title Not Found

Title Not Found

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Published: May 25, 2026

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

Journal: Diabetes, obesity & metabolism

Published: May 14, 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: April 24, 2026

Management of brain-heart multimorbidity: a clinical practice guideline.

Management of brain-heart multimorbidity: a clinical practice guideline.

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Published: March 30, 2026

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: March 12, 2026

VCING Scoring and White Matter Arteriolosclerosis Show Relationships to Dementia Status and White Matter Damage in an Unselected Ageing Brain Cohort.

VCING Scoring and White Matter Arteriolosclerosis Show Relationships to Dementia Status and White Matter Damage in an Unselected Ageing Brain Cohort.

Journal: Neuropathology and applied neurobiology

Published: February 05, 2026

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Journal: Cardiovascular diabetology

Published: January 26, 2026

Showing 1-12 of 119

Last Updated: 09/26/2026